UNICHEMLAB
Pharmaceuticals & Drugs
₹418.85
0.00 (0.00%)
Market Cap | 2,961 Cr | EPS | -18.9 | High | 424.95 | ||
Stock P/E | 0.0 | Net Profit Margin | -5.9 | Low | 416.15 |
Performance
Today’s Low
Today’s High
416.15
424.95
52W Low
52W High
264.8
449
Open Price | 419.95 | Volume | 51 |
Prev. Close | 420.8 |
Fundamentals
Market Cap | 2,961 Cr | ROE | -8.0% | ||
P/E Ratio(TTM) | 0.0 | EPS(TTM) | 0.0 | ||
P/B Ratio | 1.2 | Dividend Yield | 0.0% | ||
Industry P/E | 40.0 | Book Value | 342.0 | ||
Face Value | 2.0 |
About the Company
Unichem Laboratories, incorporated in 1962, is engaged in manufacturing formulations, pharmaceuticals and active pharmaceutical ingredients (APIs). The company was promoted by the late Amrut Mody, a pioneer in the Indian pharmaceuticals business.
The company offers products in therapeutic areas like gastro-intestinal, cardiovascular, diabetes, psychiatry, neurology, anti-bacterial, anti-infective and pain management, among others.
Headquartered in Mumbai, the company operates at five manufacturing locations in Roha (Maharashtra), Goa,
The company’s manufacturing facilities have received approval from various international agencies namely UK MHRA, MCC (
Unichem also operates a research and development facility located at Jogeshwari (Mumbai). This facility conducts research in area of Novel Drug Delivery Systems (NDDS) and develops non-infringing routes for the manufacture of products directed at the regulated markets.
Milestones
1944- Unichem was commissioned by Late Amrut Mody.
1952- The company forayed into exporting activities.
1953- Unichem entered into hormonal products segment. The same year it launched UNIPROGESTIN.
1962- The company collaborated with foreign entity UCB for bulk-drugs. It set up its first formulation plant at Jogeshwari. The company got listed at Bombay Stock Exchange. Unichem launched OESTROGEN and Progestin.
1963- The company entered co-marketing of formulations tie up with Uni Sankyo.
1968- Unichem set up a formulation plant at
1970- As part of back integration strategy, the company commissioned manufacturing of Anti-TB Drugs.
1972- As an acknowledgement for Late Amrut Mody’s pioneering effort in Indian pharma industry, he was awarded Padma Bhushan.
1973- Unichem's research laboratory was recognised for Phd work by
1976- The company set up a fine chemicals unit at Roha.
1978- Unichem commissioned its Roha bulk drug plant.
1979- The company received its first clearance from drug authorities for NEFEDIFINE.
1983- Unichem received the USFDA approval for hydrochlorothiazide manufactured at the Jogeshwari plant. The company introduced Anti-TB - Isoniazid, Rifampicin in white tablet form for the first time in
1984- UNISEARCH was established in collaboration with Upjohn. The company forayed anti-biotic segment and launched Ampoxin (Ampicillin and Cloxacillin combination).
1987- The company entered the animal health care business.
1994-1999- Unichem underwent thorough restructuring and transformation in line with future growth strategies.
1996- Two companies namely Unichem Exports and Unisearch was merged with Unichem Laboratories.
1997- The company’s formulation plant located at
1998- The company’s formulations plant located at Baddi was fully operational.
1997-2000- The company implemented BaaN ERP.
1999- Unichem set up a modern multipurpose bulk drug plant located at Roha. Molecular generics division was launched.
2000- The drug major received South African Health Authority and UK MCA (MHRA) certifications for
2001- Unichem set up new research and development centre at Mumbai. The same year it also set up New Biosciences R&D Centre located at
2002- It formed a joint venture in
2002-2003- The company divested its animal healthcare division. It established subsidiaries in
2004- Unichem conducted restructuring of Unisearch and launched of Unisearch CD Division.
2005- The company set up of new pharma technology development center located at
2006- The company received USFDA certification for the Goa Plant. It launched specialities division. In the same year it acquired 100% stake in Niche Generics,
2007- Unikare division launched that catered to Dermatology and Allied therapies segment.
2013 - 14
• Commissioning of new R&D centre at Goa
• US FDA re-certification of Pithampur(API) Plant
• Acquired API Facility in Kolhapur, Maharashtra
2015 – 16
• Successful completion of US FDA Inspection at three plants
• Expansion of Goa Formulations Plant completed, increasing the capacities significantly
• Unienzyme launched for OTC market
Parent Organization | Unichem Laboratories Ltd. | Managing Director | Pabitrakumar Kalipada Bhattacharyya | ||
Founded | 1962 | NSE Symbol | UNICHEMLAB |
Financials
All values are in Rs Cr
Shareholding Pattern
Domestic Institutions
9.53%
Foreign Institutions
1.50%
Mutual Funds
8.08%
Promoters
50.93%
Domestic Institutions
9.53%
Foreign Institutions
1.50%
Mutual Funds
8.08%
Promoters
50.93%
Domestic Institutions
9.53%
Foreign Institutions
1.50%
Mutual Funds
8.08%
Promoters
50.93%
Domestic Institutions
9.53%
Foreign Institutions
1.50%
Mutual Funds
8.08%
Promoters
50.93%
Domestic Institutions
9.53%
Foreign Institutions
1.50%
Mutual Funds
8.08%
Promoters
50.93%
Peer Comparison
Company | 52 Week | Market Price | P/E Ratio | Financials | Share Holding |
---|---|---|---|---|---|
418.85(-0.5%) | 0.0 | ||||
324.95(7.8%) | 36.4 | ||||
589.5(2.5%) | 30.1 | ||||
125.2(2.0%) | 0.0 |